Promising Newer Molecular-Targeted Therapies in Head and Neck Cancer

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Drugs

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/00003495-200868120-00001PMID 18681486
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An analysis of safety in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) receiving chemotherapy (CT) with or without panitumumab (pmab) in a phase III clinical trial (SPECTRUM).

  2016cited by this paper
• Cetuximab

  2012influential reference
• Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Results of the randomized phase II TREMPLIN study.

  2011cited by this paper
• Predictors of competing mortality in advanced head and neck cancer.

  2010cited by this paper
• Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

  2010cited by this paper
• Phase II study of sunitinib malate in head and neck squamous cell carcinoma

  2010cited by this paper
• Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.

  2010cited by this paper
• Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.

  2009cited by this paper
• Phase II Multicenter Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndrome.

  2009cited by this paper
• The Changing Face of Head and Neck Cancer in the 21st Century: The Impact of HPV on the Epidemiology and Pathology of Oral Cancer

  2009cited by this paper
• Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

  2009cited by this paper
• A phase III randomized, placebo-controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): A trial of the Eastern Cooperative Oncology Group (ECOG).

  2009cited by this paper
• Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin

  2009cited by this paper
• Platinum-based chemotherapy plus cetuximab in head and neck cancer.

  2008cited by this paper
• Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.

  2008cited by this paper
• Targeting angiogenesis in head and neck cancer.

  2008cited by this paper
• Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy

  2008cited by this paper
• Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer

  2007cited by this paper
• Computational identification of inhibitors of protein-protein interactions.

  2007cited by this paper
• Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG, E2303)

  2007cited by this paper
• Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN)

  2007cited by this paper
• Targeting angiogenesis in head and neck cancer.

  2007cited by this paper
• A phase I, open-label study (EGF 100262) of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)

  2007cited by this paper
• Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study

  2007cited by this paper
• Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.

  2007cited by this paper
• Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib.

  2007influential reference
• Molecular design and clinical development of VEGFR kinase inhibitors.

  2007cited by this paper
• Cancer Statistics, 2007

  2007cited by this paper
• Antitumor effects of ZD6474 on head and neck squamous cell carcinoma.

  2007cited by this paper
• Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.

  2007cited by this paper
• Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer.

  2007cited by this paper
• Malignancies of the head and neck: the role for molecular targeted agents

  2007cited by this paper
• Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.

  2007cited by this paper
• Role of insulin-like growth factor 1 receptor signalling in cancer.

  2007cited by this paper
• EGFR targeting of solid tumors.

  2007cited by this paper
• Trends in head and neck cancer incidence in relation to smoking prevalence

  2007cited by this paper
• Cetuximab (C-mab) and chemo-radiation (CT-RT) for loco-regional advanced squamous cell carcinoma of the head and neck (HNC): A phase II study

  2007cited by this paper
• pKDR/KDR ratio predicts response in a phase I/II pharmacodynamic study of erlotinib and bevacizumab for recurrent or metastatic head and neck cancer (HNC)

  2007cited by this paper
• Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study.

  2007influential reference
• Randomized phase II study of concomitant chemoradiotherapy with 5-fluorouracil-hydroxyurea (FHX) compared to FHX and bevazicumab (BFHX) in intermediate stage head and neck cancer (HNC)

  2007cited by this paper
• Biology of interactions: antiepidermal growth factor receptor agents.

  2007influential reference
• Phase II trial of pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): An interim analysis

  2007cited by this paper
• Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts

  2007cited by this paper
• Insulin-like Growth Factor Receptor as a Therapeutic Target in Head and Neck Cancer

  2007influential reference
• Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer.

  2006cited by this paper
• Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

  2006cited by this paper
• Synergistic Antitumor Activity of ZD6474, An Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, with Gemcitabine and Ionizing Radiation against Pancreatic Cancer

  2006cited by this paper
• A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).

  2006cited by this paper
• A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers

  2006cited by this paper
• Head and neck cancer: past, present and future

  2006cited by this paper
• Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck.

  2006cited by this paper
• Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.

  2006cited by this paper
• Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.

  2006cited by this paper
• Induction chemotherapy (CT) with weekly paclitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck (HN).

  2006cited by this paper
• EGFR-targeting monoclonal antibodies in head and neck cancer.

  2006cited by this paper
• Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck

  2006cited by this paper
• Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck

  2006cited by this paper
• A phase II trial of sorafenib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): A Southwest Oncology Group (SWOG) trial

  2006cited by this paper
• The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications

  2006cited by this paper
• Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.

  2005cited by this paper
• Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.

  2005cited by this paper
• Radiation Oncology BioMed Central Review

  2005cited by this paper
• Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2

  2005cited by this paper
• Trends in incidence and prognosis for head and neck cancer in the United States: A site‐specific analysis of the SEER database

  2005cited by this paper
• Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.

  2005cited by this paper
• The IGF-1 receptor and its contributions to metastatic tumor growth—novel approaches to the inhibition of IGF-1R function

  2005influential reference
• Preliminary results of a phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and/or metastatic squamous-cell carcinoma of the head and neck

  2005cited by this paper
• Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&N Ca)

  2005cited by this paper
• Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

  2005cited by this paper
• Prognostic Significance of Vascular Endothelial Growth Factor Immunohistochemical Expression in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis

  2005cited by this paper
• Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling

  2005cited by this paper
• Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial.

  2005cited by this paper
• A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group

  2005cited by this paper
• Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.

  2004cited by this paper
• Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity.

  2004cited by this paper
• Insulin-like growth factors and neoplasia.

  2004cited by this paper
• Uptake of the anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 in tumors of subjects with head and neck squamous cell carcinoma (HNSCC).

  2004cited by this paper
• Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody.

  2004cited by this paper
• Uptake of the anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 in tumors of subjects with head and neck squamous cell carcinoma (HNSCC)

  2004cited by this paper
• Development of the Novel Biologically Targeted Anticancer Agent Gefitinib

  2004cited by this paper
• Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.

  2004cited by this paper
• The expanding role of systemic therapy in head and neck cancer.

  2004cited by this paper
• Insulin-like growth factors and neoplasia

  2004cited by this paper
• Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.

  2003influential reference
• Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells.

  2003cited by this paper
• The p53 network in head and neck cancer.

  2003cited by this paper
• The ErbB receptors and their role in cancer progression.

  2003cited by this paper
• The role of ubiquitylation in signaling by growth factors: implications to cancer.

  2003cited by this paper
• Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains.

  2002cited by this paper
• Ligand-induced, receptor-mediated dimerization and activation of EGF receptor.

  2002cited by this paper
• The Roles of JNK1 and Stat3 in the Response of Head and Neck Cancer Cell Lines to Combined Treatment with All trans‐retinoic Acid and 5‐Fluorouracil

  2002cited by this paper
• End points for new agents in induction chemotherapy for locally advanced head and neck cancers.

  2002cited by this paper
• Epidermal growth factor receptor dependence in human tumors: more than just expression?

  2002cited by this paper
• The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

  2002cited by this paper
• Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association.

  2001cited by this paper
• Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation.

  2001cited by this paper
• EGFR and cancer prognosis.

  2001cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy.

  2001influential reference
• The ErbB receptor tyrosine family as signal integrators.

  2001cited by this paper

• Local Delivery of miR-27a* Using Ultrasound-Targeted Microbubble Cavitation Inhibits Squamous Cell Carcinoma Growth.

  2025cites this paper
• Oral Mucositis

  2022cites this paper
• General Introduction to Head and Neck Cancer: Etiology, Symptoms, Diagnosis, Staging, Prevention, and Treatment

  2021cites this paper
• Anti-EGFR therapies in nasopharyngeal carcinoma.

  2020cites this paper
• Head and neck cancer management and cancer stem cells implication

  2019cites this paper
• Identification of Differentially Expressed Proteins from Smokeless Tobacco Addicted Patients Suffering from Oral Squamous Cell Carcinoma

  2019cites this paper
• Novel and Emerging Chemotherapeutic Agents in Head and Neck Cancer

  2019cites this paper
• Checkpoint inhibitors in head and neck cancer

  2019cites this paper
• Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review

  2018cites this paper
• Effects of sunitinib targeted chemotherapy on the osseointegration of titanium implants.

  2018cites this paper
• Precision Therapy of Head and Neck Squamous Cell Carcinoma

  2018cites this paper
• Radiotherapy plus EGFR inhibitors: synergistic modalities

  2017cites this paper
• Soluble guanylate cyclase stimulators increase sensitivity to cisplatin in head and neck squamous cell carcinoma cells.

  2017cites this paper
• Treatment Outcomes of 257 Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Treated with Nimotuzumab Plus Intensity-Modulated Radiotherapy with or without Chemotherapy: A Single-Institution Experience

  2017cites this paper
• In Vitro and In Vivo Synergistic Antitumor Activity of the Combination of BKM120 and Erlotinib in Head and Neck Cancer: Mechanism of Apoptosis and Resistance

  2017cites this paper
• Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis

  2016cites this paper
• Oral squamous cell carcinoma: Key clinical questions, biomarker discovery, and the role of proteomics.

  2016cites this paper
• Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells

  2016cites this paper
• ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.

  2016cites this paper
• Genomic insights into head and neck cancer

  2016cites this paper
• Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives

  2016cites this paper
• Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer

  2016cites this paper
• A Scrotal Ulcer with Degenerating Inguinal Lymph Nodes in an HIV Positive Patient - Infection or Malignancy?

  2016cites this paper
• Current Role of Dacomitinib in Head and Neck Cancer

  2016cites this paper
• Recent Progress in Therapeutic Treatments and Screening Strategies for the Prevention and Treatment of HPV-Associated Head and Neck Cancer

  2015influential citation
• Pneumatosis Cystoides Intestinalis after Cetuximab Chemotherapy for Squamous Cell Carcinoma of Parotid Gland

  2015cites this paper
• Nuclear expression of p65 (RelA) in patients receiving post-operative radiotherapy for locally advanced squamous cell carcinoma of the head and neck

  2015cites this paper
• Definitive intensity modulated radiotherapy in locally advanced hypopharygeal and laryngeal squamous cell carcinoma: mature treatment results and patterns of locoregional failure

  2015cites this paper
• Combining antiangiogenic therapy and radiation in nasopharyngeal carcinoma

  2015cites this paper
• Targeting HIF1α Peri-operatively Increased Post-surgery Survival in a Tongue Cancer Animal Model

  2015cites this paper
• Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.

  2015cites this paper
• Update on Benign and Inflammatory Skin Disease Secondary to Transplant Medication

  2015cites this paper
• Management of Cutaneous Squamous Cell Carcinoma in Organ Transplant Recipients

  2015cites this paper
• Pharmacogenomics for Oral Disease

  2015cites this paper
• Advances in Head and Neck Surgery

  2015cites this paper
• Biomarkers for Individualized Oral Cancer Therapy

  2015cites this paper
• Opportunities and Challenges for the Future of Personalized Oral Healthcare

  2015cites this paper
• Therapeutic strategy for cancer immunotherapy in head and neck cancer

  2015cites this paper
• (131)I-Nimotuzumab - A potential radioimmunotherapeutic agent in treatment of tumors expressing EGFR.

  2015cites this paper
• Role of EGFR as a prognostic factor for survival in head and neck cancer: a meta-analysis

  2014cites this paper
• Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies

  2014influential citation
• Correlation between vascular endothelial growth factor expression and presence of lymph node metastasis in advanced squamous cell carcinoma of the larynx

  2014cites this paper
• Clinical application of genetics to guide prevention and treatment of oral diseases

  2014cites this paper
• ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors.

  2014cites this paper
• Combination antiangiogenic therapy and radiation in head and neck cancers.

  2014cites this paper
• Squamous cell carcinoma of the scrotum: A look beyond the chimneystacks.

  2014cites this paper
• Gentherapie und Stammzellen für das Innenohr

  2014cites this paper
• Incomplete epithelial-mesenchymal transition in p16-positive squamous cell carcinoma cells correlates with β-catenin expression.

  2014cites this paper
• Nimotuzumab in combination with radiotherapy in high grade glioma patients

  2014cites this paper
• The mutational spectrum of squamous-cell carcinoma of the head and neck: targetable genetic events and clinical impact.

  2014cites this paper
• Heterogeneity of 11q13 region rearrangements in laryngeal squamous cell carcinoma analyzed by microarray platforms and fluorescence in situ hybridization

  2013cites this paper
• Advanced Squamous Cell Carcinoma of the Skin

  2012cites this paper
• High-Throughput Screening for Novel Anti-cancer Radiosensitizers for Head and Neck Cancer

  2012cites this paper
• The role of targeted molecular inhibitors in the management of advanced nonmelanoma skin cancer.

  2011cites this paper
• Oral complications of targeted cancer therapies: a narrative literature review.

  2011cites this paper
• Cetuximab

  2010cites this paper
• Feasibility and Activity of Sorafenib and Sunitinib in Advanced Penile Cancer: A Preliminary Report

  2010cites this paper
• Quinacrine Enhances Cisplatin-Induced Cytotoxicity in Four Cancer Cell Lines

  2010cites this paper
• Emerging molecular targeted therapies in the treatment of head and neck cancer

  2009cites this paper